Coiled Therapeutics completes enrollment in AO-252 trial cohorts

Coiled Therapeutics completed enrollment of six patients across two AO-252 softgel dose cohorts, with three patients each receiving 120mg twice daily and 160mg once daily. The company plans to dose up to 30 patients by year-end 2026 and expects initial safety and pharmacokinetic data by the end of 2026. Earlier tablet-formulation data showed an 80% clinical-benefit rate in five twice-daily patients versus 40% in five once-daily patients, although the sample sizes remain very small.

Analysis

This is a low-information operational milestone rather than a clinical validation event. With only six patients in the new formulation cohorts and no disclosed safety, pharmacokinetic, response, cash-runway, or enrollment-site data, there is no basis to underwrite either dose selection or the probability that the formulation improves therapeutic index. The key near-term market effect is likely retail-flow driven in an illiquid micro-cap, where modest promotional attention can create price volatility disproportionate to fundamental value.

The investable catalyst window begins with the initial safety/PK dataset expected by year-end, not the enrollment update. A favorable result requires more than tolerability: the softgel must demonstrate materially tighter exposure variability and exposure levels consistent with biologic activity, while preserving the twice-daily efficacy signal suggested by the earlier very small dataset. Absent those elements, the program faces a likely delay to dose expansion, incremental financing needs, and dilution risk before a registrationally relevant efficacy signal emerges.

Contrarian view: the apparent benefit-rate differential between dosing schedules is not evidence of a superior regimen at this sample size and should not support a durable re-rating. The more relevant structural question is whether TACC3 biomarker selection identifies a commercially meaningful population versus a narrow, heterogeneous subset with competing targeted-therapy options. There is no read-through to APP or SMCI despite their inclusion in the supplied ticker set.

Key Decisions for Investors

• No fundamental long in COIL ahead of the year-end safety/PK release; treat any near-term rally as event/flow-driven unless accompanied by disclosed exposure-response data, objective response metrics, and a credible cash runway through dose expansion.
• Place a COIL monitoring trigger for the initial softgel dataset: consider a small catalyst long only if pharmacokinetic variability is demonstrably reduced versus tablet, no dose-limiting toxicity emerges, and management funds the expansion plan without a deeply discounted equity raise. Size for binary micro-cap risk, not core exposure.
• For holders, reduce exposure into unexplained liquidity-led spikes and retain only event-sized risk through data. Thesis is falsified by safety signals, failure to show improved bioavailability, enrollment slippage, or financing that materially expands the share count before efficacy data.
• Do not express this through APP or SMCI; neither has an identifiable commercial, supply-chain, or valuation linkage to COIL's clinical program.